Natural Killer Cells Therapeutics Market Outlook - 2026
The global natural killer cells therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026. Natural killer cells are large granular lymphocytes that respond quickly to a pathological challenge. In addition, they are responsible for producing immunoregulatory cytokines. Moreover, they act as an important component of the innate immune system of a human. The key role of NK cells is to generate an immune response against malignancies and viral infections.
In the past several years, these cells were being used in various molecular and combinational therapies, which increased the adoption of such treatments. Furthermore, they can be used as an effective therapeutic tool against infectious diseases and as an anti-cancer alternative to T cells. Research activities are being carried out to culture NK cells in ex vivo conditions, thus consequently exploring and developing newer therapies for the treatment of infections and tumors.
Rise in adoption of NK cells for the treatment of cancer, infections, and liver diseases is a key factor that drives the growth of the natural killer cells therapeutics market. In addition, NK cells play a pivotal role in tumor immune-surveillance, which boosts the adoption of NK therapeutics across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global market growth. However, lack of specificity and poor in-vivo survival of the cells limit the natural killer cells therapeutics market growth. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. On the contrary, significant surge in R&D activities toward development of immunotherapy in the developing economies is anticipated to offer lucrative opportunities as per the NK cell therapeutics market forecast.
Therapeutics segment review
The global natural killer cells therapeutics market is segmented based on therapeutics, application, end user, and region. Based on therapeutics, the market is classified into NK cell therapies and NK cell directed antibodies. Immunotherapy has emerged as an ideal therapeutic solution to improve the clinical outcome against various malignancies and tumors. Recently, several advances have been made in NK cells therapies such as target recognition, adoptive therapy, and improvement in cellular cytotoxicity.
Application segment review
The applications covered in the study include cancer, gastrointestinal diseases, immunoproliferative disorders, and others. The cancer segment accounted for a major share in 2018, and is expected to continue this trend during the forecast period, due to increase in adoption of NK cell therapies for various types of cancers such as acute myeloid leukemia, Hodgkin's lymphoma, hematologic malignancies, solid tumors, cutaneous T cell lymphoma, and head & neck cancer. However, the gastrointestinal disease segment is anticipated to witness rapid growth in the near future, owing to rise in incidence of diseases related to gastrointestinal tract.
End-user segment review
Depending on end user, the global natural killer cells therapeutics market is classified into hospitals, research centers & institutes, and others. Various ongoing research activities such as NK cells & immunological memory improvements, stress-induced self-recognition, and cell-based therapies are currently in progress. Moreover, certain immuno-monitoring studies are being performed for determining the usage of NK cells. In hospitals, natural killer cell therapies are used to treat cancers using genetic engineering. Moreover, these cells are used as a therapeutic tool to cure immunoproliferative disorders, gastrointestinal diseases, various cancers, and infectious diseases due to their ability to detect transformed cells. Furthermore, several clinical trials are performed to evaluate the safety and the anti-tumor effects of NK cells. The primary objective of the study is to determine the safety of NK cells’ doses against cancers and malignancies. In addition, NK cell therapeutics involves clinical and experimental research to provide cost-effective treatments with improved success rates. Currently, research is being carried out for adoptive transfer of haploidentical natural killer cells for the consolidated therapy of pediatric acute myeloid leukemia. Thus, NK cell therapeutics have promising applications in various research institutes.
Region segment review
The North America natural killer cells therapeutics market share accounted for the highest share in 2018 and is expected to continue its dominance throughout the forecast period. This is attributed to significant increase in prevalence of cancer in this region. However, the Asia-Pacific market is anticipated to grow at the fastest pace, owing to increase in number of patients suffering from cancer, surge in geriatric population, and improvement in healthcare facilities. However, the complexity in regulatory frameworks regarding the approval of immunotherapy is expected to hamper the market growth. Conversely, high incidence of cancer is anticipated to boost the growth of cancer immunotherapy market, which in turn will fuel the growth of the NK cells therapeutics market.
The global natural killer cells therapeutics market analysis provides insights regarding the highly competitive nature of the prominent players in the market and the various strategies adopted for garnering maximum share. These include expansion of their geographical presence through collaborations and focus on R&D activities for NK cells. Major players operating in the market include Affimed N.V., Celgene Corporation, Fate Therapeutics, Fortress Biotech, Glycostem Therapeutics BV, Innate Pharma S.A., Nantkwest Inc., Nkarta Therapeutics, Inc., NKT Therapeutics Inc., and Ziopharm Oncology Inc.
Key Benefits for Natural Killer Cells Therapeutics Market:
- This report entails a detailed quantitative analysis along with the current natural killer cells therapeutics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The global natural killer cells therapeutics market size and estimations are based on a comprehensive analysis of key developments.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Natural Killer Cells Therapeutics Market Segments:
By Therapeutics
- NK Cell Therapies
- NK Cell Directed Antibodies
By Application
- Cancer
- Gastrointestinal Diseases
- Immunoproliferative Disorders
- Others
By End User
- Research Centers & Institutes
- Hospitals
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Natural Killer Cells Therapeutics Market Report Highlights
| Aspects | Details |
 By THERAPEUTICS |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | CELGENE CORPORATION, NKT THERAPEUTICS INC., NANTKWEST INC, ZIOPHARM ONCOLOGY INC., AFFIMED N.V., INNATE PHARMA SA, NKARTA THERAPEUTICS, INC., FORTRESS BIOTECH, GLYCOSTEM THERAPEUTICS BV, FATE THERAPEUTICS INC. |
Analyst Review
Natural killer cell therapeutics are majorly utilized in the healthcare sector, owing to increase in prevalence of diseases, including cancer, gastrointestinal diseases, and others. In accordance to several interviews conducted, the utilization of natural killer cell therapeutics is projected to witness a significant increase, owing to high incidence of cancer across the globe.
The market is largely consolidated, and several clinical stage manufacturers have focused on offering advanced and novel natural killer cell therapeutics, which aid in the market growth. Moreover, rise in government expenditure in the healthcare sector and increase in awareness of immunotherapy to treat various diseases are anticipated to boost the market growth. Furthermore, ongoing R&D activities in cancer immunotherapy to provide advanced features for patients for effective treatment fuel the market growth.
Region wise, North America dominated the global natural killer cell therapeutics market in 2018, accounting for the highest market share of 40%, and is expected to continue its dominance throughout the forecast period. This is attributed to significant increase in prevalence of cancer in this region.
Loading Table Of Content...
